News Release

Permission Granted In Canada For Phase II Opiate Study To Begin

Date: Feb 13, 2002

TSX Venture Exchange Trading Symbol: WXI
http://www.wextech.ca
E-mail: wex@wextech.ca

International Wex Technologies Inc., the "Company" is pleased to announce that we have received a No Objection Letter from Health Canada. This allows the Company's opiate withdrawal treatment, using Tetrodin(tm), to be administered to patients in Canada.

With this letter the Company can proceed to arrange for the double-blind, placebo controlled, fixed repeated-dose efficacy and safety study of Tetrodin(TM) in opiate withdrawal patients. The clinical facility will be at Ventana Clinical Research Corporation in Toronto. Dr. E. Sellers is the qualified investigator and the co-investigator is Dr. M. Romach. A total of 16 individuals will be entered into the study based upon healthy male and females over the age of 18 who use methadone as maintenance and are physically dependent upon opiates

In the area of neuro-bioscience, the Company is focusing on the fields of pain management, drug addiction treatment and anaesthesia. The Company is developing products that contain a sodium channel blocking compound and derivatives extracted from natural organic substance using its proprietary manufacturing technology.

For additional information on our products, view the Company website at http://www.wextech.ca or call Howard Milne, V.P. Corporate Communications, at 604-683-8880 or 1-800-722-7549.

Per: Donna Shum, Corporate Secretary

The Canadian Venture Stock Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this News Release.